Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2026-02-03 @ 1:39 AM
Study NCT ID:
NCT02437318
Status:
COMPLETED
Last Update Posted:
2025-02-13
First Post:
2015-04-22
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | BYL719 | View |
| None | HR+ | View |
| None | HER2-negative | View |
| None | advanced breast cancer | View |
| None | alpelisib | View |
| None | fulvestrant | View |
| None | PI3K | View |
| None | Phase III | View |
| None | ER+ | View |
| None | PgR+ | View |
| None | men | View |
| None | postmenopausal | View |
| None | aromatase inhibitor | View |
| None | neoplasms | View |